Zyvox Safety Alert Undercuts PhRMA Good News Events
This article was originally published in RPM Report
Talk about bad timing. A March 16 safety alert issued by the Food & Drug Administration regarding Pfizer Inc.'s antibiotic linezolid (Zyvox) couldn't have come at a worse time. If there was any doubt left on the point, it is gone now: drug safety will be the dominant theme for the pharmaceutical industry in 2007.
You may also be interested in...
FDA is being more proactive about issuing safety warnings. But, as GSK's experience with Advair shows, what looks like bad news to Wall Street may not matter as much to physicians. FDA is well aware of the limitations of its risk communication techniques, but for now the agency is commited to transparency.
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.